for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adaptimmune Therapeutics PLC - ADR

ADAP.OQ

Latest Trade

0.81USD

Change

-0.01(-1.13%)

Volume

11,195

Today's Range

0.80

 - 

0.84

52 Week Range

0.71

 - 

6.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.82
Open
0.83
Volume
11,195
3M AVG Volume
6.84
Today's High
0.84
Today's Low
0.80
52 Week High
6.55
52 Week Low
0.71
Shares Out (MIL)
630.95
Market Cap (MIL)
91.49
Forward P/E
-0.64
Dividend (Yield %)
--

Latest Developments

More

Adaptimmune Qtrly Loss Per Share $0.06

Adaptimmune Therapeutics PLC Files For Mixed Shelf Of Up To $400 Million

Adaptimmune And Noile-Immune Announce Pact To Develop Spear T-Cell Products For Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adaptimmune Therapeutics PLC - ADR

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Industry

Biotechnology & Drugs

Contact Info

60 Jubilee Avenue

+44.1235.430000

https://www.adaptimmune.com/

Executive Leadership

David M. Mott

Non-Executive Independent Chairman of the Board

Adrian Rawcliffe

Chief Executive Officer, Director

Michael R. Garone

Interim Chief Financial Officer

William C. Bertrand

Chief Operating Officer

John Lunger

Chief Patient Supply Officer

Key Stats

2.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2016

-1.020

2017

-0.780

2018

-0.960

2019(E)

-1.362
Price To Earnings (TTM)
--
Price To Sales (TTM)
48.85
Price To Book (MRQ)
0.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-63.86
Return on Equity (TTM)
-55.60

Latest News

Latest News

BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04

* ADAPTIMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Adaptimmune Therapeutics Reports Quarterly Loss Per Ordinary Share Of $0.05

* ADAPTIMMUNE REPORTS FOURTH QUARTER / FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Adaptimmune Announces Responses In Second Solid Tumor Indication

* ADAPTIMMUNE ANNOUNCES RESPONSES IN SECOND SOLID TUMOR INDICATION WITH NY-ESO SPEAR T-CELLS

BRIEF-Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK

* ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING

BRIEF-Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells

* ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates

BRIEF-Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics

* Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing Source text: (http://bit.ly/2wSEc1U)

GSK bets on pioneering cancer therapy with Adaptimmune deal

GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.

BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

* Adaptimmune Therapeutics Plc - GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

BRIEF-Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting

* Adaptimmune announces an oral presentation on data from NY-ESO study in Synovial Sarcoma and four trials in progress posters at the American Society Of Clinical Oncology (ASCO) annual meeting

BRIEF-Adaptimmune reports initiation of study to evaluate spear t-cell therapy

* Adaptimmune announces initiation of study to evaluate spear t-cell therapy targeting mage-a4 in multiple solid tumors

BRIEF-Adaptimmune announces initiation of study to evaluate SPEAR T-cell therapy

* Adaptimmune announces initiation of study to evaluate SPEAR T-cell therapy targeting AFP in liver cancer Source text for Eikon: Further company coverage:

BRIEF-Adaptimmune Q1 loss per share $0.05

* Adaptimmune therapeutics plc - offerings in march and april raised net proceeds of $103.2 million; operations funded through to late 2019

BRIEF-Adaptimmune Therapeutics announces registered direct offering of ADS

* Adaptimmune therapeutics plc announces registered direct offering of american depositary shares

BRIEF-Adaptimmune Therapeutics prices public offering of American Depositary Shares

* Adaptimmune Therapeutics PLC prices public offering of American Depositary Shares

BRIEF-Adaptimmune Therapeutics proposes public offering of American Depositary Shares

* Adaptimmune Therapeutics Plc proposes public offering of American Depositary Shares

BRIEF-Adaptimmune Therapeutics names Helen Tayton-Martin as chief business officer

* Adaptimmune Therapeutics- appointment of co-founder, Helen Tayton-Martin to role of chief business officer, William (Bill) Bertrand, Jr., J.D., as COO Source text for Eikon: Further company coverage:

BRIEF-Adaptimmune Therapeutics reports Q4 loss per share $0.04

* Adaptimmune reports fourth quarter and full year 2016 financial results

BRIEF-Adaptimmune announces update on clinical data from NY-ESO Spear T-cell synovial sarcoma study

* Adaptimmune announces update on clinical data from NY-ESO Spear T-cell synovial sarcoma study at the 2016 annual meeting of the Connective Tissue Oncology Society (CTOS)

BRIEF-Adaptimmune presents preclinical data from SPEAR T-cell

* Adaptimmune presents preclinical data from a new, wholly-owned Spear T-cell and a second generation spear T-cell at the 31st annual meeting of the Society For Immunotherapy for Cancer (sitc)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up